Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA protective dietary compounds

Kavita Bisht¹, Karl-Heinz Wagner², Andrew C. Bulmer¹*

¹Heart Foundation Research Centre, Faculty of Health, Griffith University, Australia

²Department of Nutritional Science, Emerging Field Oxidative Stress and DNA Damage, University of Vienna, Austria.

*Corresponding author: Andrew C. Bulmer
Heart Foundation Research Centre
Faculty of Health, Griffith University
Parklands Drive
4222, Southport, Australia.
Ph: +61(0) 7 55528215
Fax: +61(0)7 55528908
e-mail: a.bulmer@griffith.edu.au
Abstract

Numerous dietary compounds, ubiquitous in fruits, vegetables and spices have been isolated and evaluated during recent years for their therapeutic potential. These compounds include flavonoid and non-flavonoid polyphenols, which describe beneficial effects against a variety of ailments. The notion that these plant products have health promoting effects emerged because their intake was related to a reduced incidence of cancer, cardiovascular, neurological, respiratory, and age-related diseases. Exposure of the body to a stressful environment challenges cell survival and increases the risk of chronic disease developing. The polyphenols afford protection against various stress-induced toxicities through modulating intercellular cascades which inhibit inflammatory molecule synthesis, the formation of free radicals, nuclear damage and induce antioxidant enzyme expression. These responses have the potential to increase life expectancy. The present review article focuses on curcumin, resveratrol, and flavonoids and seeks to summarize their anti-inflammatory, cytoprotective and DNA protective properties.

Key words: nutrition, polyphenols, chronic illness, anti-inflammatory, haem oxygenase, cytoprotective, DNA protection
1. Introduction

Organisms are continually exposed to various stresses derived from natural and chemical sources. These cellular stresses disturb cellular and systems homeostasis and can, if disturbed chronically, contribute to the onset of cardiovascular, neurodegenerative, respiratory diseases in addition to cancer and stroke. The social and economic costs of these diseases are devastating, affecting the lives of millions of persons world-wide, each year (Bengmark et al., 2009). Cytotoxins mechanisms of action include the activation of inflammatory pathways, release of reactive oxygen species (ROS), formation of DNA-adducts, and inhibition of cytoprotective proteins. An understanding of the toxicological mechanisms and identification of dietary substances that can protect from cytotoxicity will continue to reduce the burden of disease in future. Reducing the burden of disease could be achieved by providing the general population with easily accessible and relatively inexpensive foods with health benefits.

In recent years, the use of natural plant products has attracted increased attention among clinicians and the public for the prevention/treatment of various chronic diseases. Consumption of natural products reduces the risk of developing pathological conditions, including cancer, nervous system disorders, cardiovascular, genetic, and inflammatory diseases (Jurenka, 2009; Newman and Cragg, 2007). Plants contain numerous bioactive molecules that can improve the body’s resistance to cellular stress and prevent the cytotoxicity of various agents. Among them, polyphenols such as curcumin, resveratrol (non-flavonoids), and flavonoids have received much attention for their ability to reduce cellular stress-induced injury (Mattson et al., 2007). These polyphenols inhibit toxin-mediated stress responses via their anti-inflammatory and antioxidant
properties in addition to inducing the expression of cytoprotective proteins (Aggarwal and Sung, 2009; Di Carlo et al., 1999; Shakibaei et al., 2009).

In this review, we present an overview of the anti-inflammatory, cyto-protective, and DNA-protective properties of curcumin, resveratrol, and flavonoids.

2 Curcumin

Curcumin (diferuloylmethane; Fig. 1) is a bright yellow compound found in turmeric, which is derived from the rhizomes of the plant *Curcuma longa Linn*, a perennial herb of the Zingerberaceae family (Ammon and Wahl, 1991). Curcumin is comprised of curcumin I (94%), curcumin II (6%), and curcumin III (0.3%). Curcumin is a lipophilic polyphenol that is insoluble in water (Ruby et al., 1995). Table 1 summarises the most important findings presented in this section.

2.1 Anti-inflammatory properties

Curcumin mitigates inflammatory responses by inhibiting cyclooxygenase-2 (COX-2), lipoxygenase, nuclear factor (NF)-kappa B, inducible nitric oxide synthase, and nitrite oxide (NO) production in lipopolysaccharide-, IFN-γ-, or TNF-α-activated macrophages and NK cells (Bhaumik et al., 2000; Brouet and Ohshima, 1995; Surh et al., 2001). NF-kappa B is sequestered by inhibitor KappaB (IkB)α intercellularly (Karin, 1999). Curcumin inhibits the NF-kappa B activation in a TNF-α, phorbol 12-myristate 13-acetate (PMA)-, or H₂O₂-stimulated human myelomonoblastic cell line (ML-1a) by preventing the phosphorylation and degradation of IkBα (Singh and Aggarwal, 1995). PMA is an activator of protein kinase C (PKC), which is a regulator of cell proliferation and survival. In addition to PMA, TNF-α and LPS also activate
PKC, which subsequently activates NF-kappa B (Holden et al., 2008). Thus, curcumin may attenuate NF-kappaB activation by inhibiting PKC (Singh and Aggarwal, 1995). The anti-inflammatory effects of curcumin are partly mediated via inhibition of the transcription factor NF-kappa B and activator protein (AP)-1. Together, AP-1 and NF-kappaB act synergistically and may promote tumor progression. Treatment of glioma cells with 25 µM curcumin decreases AP-1 and NF-kappa B binding (Dhandapani et al., 2007). Curcumin also suppresses the activation of AP-1 in TNF-α activated bovine aortic endothelial cells (BAECs) (Bierhaus et al., 1997; Xu et al., 1997). The release of pro-inflammatory cytokines from activated immune cells plays an important role in the inflammatory response. Curcumin exerts inhibitory effects on the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-12, and IFN-γ by LPS- or PMA-stimulated splenic lymphocytes, monocytes, macrophages, and dendrite cells (Abe et al., 1999; Gao et al., 2004; Kim et al., 2005). Cell adhesion molecules are important for adhesion of T cells to antigen presenting and endothelial cells and play a prominent role in inflammation. Pre-treatment with curcumin blocked the adhesion of monocytes to endothelial cells and down-regulated expression of intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and endothelial leukocyte adhesion molecule (ELAM)-1 by interfering with NF-kappa B activation in TNF-stimulated human umbilical vein endothelial cells (HUVEC(Kumar et al., 1998).

2.2 Cyto-protective effects

Curcumin and its analogues ameliorate cytotoxicity induced by various kinds of toxins. Curcumin is generally cytoprotective, however, can also be cytotoxic in paracetamol treated rat hepatocytes. Low concentrations of curcumin reduce paracetamol-mediated lipid peroxidation,
without affecting lactate dehydrogenase (LDH; a marker of cell membrane rupture) leakage and glutathione depletion (GSH). On the contrary, at 100 times higher concentration curcumin increased LDH leakage and promoted glutathione depletion, however, still protected the cells from lipid peroxidation (Donatus et al., 1990). Thus, despite protecting from lipid peroxidation, curcumin may promote paracetamol mediated cytotoxicity by elevating the LDH-leakage and reducing GSH levels. Curcumin's cyto-protective effects may be attributed to its potent antioxidant activity. However, curcumin is conjugated to GSH, thereby reducing the intracellular GSH pool, which may increase LDH-leakage by reducing the concentration of this important thiol containing compound (Donatus et al., 1990).

Curcumin also attenuates inflammatory responses in acute or chronic inflammatory disease conditions. In rats suffering from carrageenan-induced oedema, curcumin treatment significantly reduced inflammation (Rao et al., 1982; Srivastava and Srimal, 1985). Curcumin also inhibited the 12-O-tetradecanoylphorbol-13-acetate (TPA) and arachidonic acid (AA)-induced inflammation in mouse skin epidermis (ear oedema; Huang et al., 1991). Curcumin administration to rats prior to arthritis induction mitigated joint inflammation (Funk et al., 2006). In another study, a curcumin dosage of 1200 mg daily to patients suffering from rheumatoid arthritis reduced inflammatory symptoms (Deodhar et al., 1980). Curcumin also inhibits cerulean- and ethanol-induced pancreatitis (Gukovsky et al., 2003). Daily doses of curcumin (550 mg twice/day) to patients with inflammatory bowel diseases also ameliorated the patients inflammatory symptoms (Holt et al., 2005). Administration of curcumin (375 mg) daily for 12 weeks to patients with anterior uveitis showed complete symptomatic recovery. Improvements were observed in visual acuity and aqueous flare and were accompanied by a decrease in keratic precipitates (Lal et al., 1999).
In shiga toxin (Stx) 1 or 2 treated human proximal tubule cells (HK-2), curcumin attenuated the detrimental effects of Stx 1 and 2, increasing cell viability, reducing the necrotic cell population, lowering DNA fragmentation and elevating the expression of molecular chaperone HSP 70 (Sood et al., 2001). In another study, co-administration of curcumin with H_2O_2 significantly reduced the H_2O_2-induced oxidative stress in neuroblastoma-glioma hybrid cell line (NG108-15). However, pre-treatment with curcumin before H_2O_2 challenge did not protect NG108-15 cells from oxidative damage (Mahakunakorn et al., 2003).

1-methyl-4-phenylpridinium ion (MPP^+)-induced cytotoxicity and apoptosis in rat pheochromocytoma (PC12) cells were suppressed by curcumin. Curcumin enhanced the level of Bcl-2, alleviated the loss of mitochondrial membrane potential, blocked the release of reactive oxygen species and the expression of iNOS in MPP^+-stimulated PC12 cells (Chen et al., 2006a). Pre-incubation with curcumin at 50-200 nM significantly reduced ethanol-mediated oxidative stress in HT22 hippocampal cells through inhibition of mitogen-activated protein kinase (MAPK) pathways and activation of MAPK phosphatases (MKPs)-1. Incubation of HT22 cells with curcumin led the dose dependent phosphorylation of MKP-1 which in turn inactivated MAPK pathways (Pae et al., 2009). MAPKs play an important role in cell proliferation, differentiation, stress responses, apoptosis and immune defense. A number of proteins are known to deactivate MAPKs, including tyrosine, serine/threonine and dual specificity phosphatases (Wang and Liu, 2007). In mammalian cells, the dual-specificity phosphatases, which are known as MKPs, are the primary phosphatases responsible for dephosphorylation/deactivation of MAPKs. MKP-1 is one of the MAPK-specific dual-specificity phosphatases and has been extensively studied (Boutros et al., 2008; Wang and Liu, 2007). MKP-1 dephosphorylates both phosphotyrosine and phosphothreonine residues of MAPKs and is regarded as an important
feedback control mechanism (Wang and Liu, 2007). Therefore, up-regulation of MKP-1 in HT22 cells by curcumin during ethanol stimulation may have a cyto-protective, anti-apoptotic effect (Pae et al., 2009).

Haem oxygenase (HO)-1 is an antioxidant phase 2 enzyme that degrades haem to carbon monoxide, iron and biliverdin. Curcumin induces HO-1 expression and activity. HO-1 has been suggested to be an important therapeutic target in various disease models (Ryter et al., 2006; Soares and Bach, 2009). Curcumin at 5-25 µM significantly enhanced the expression of HO-1 protein in rat astrocytes and neurons through activation of the transcription factor nuclear factor-E2-related factor (Nrf2). In addition, pre-incubation with curcumin protected the neurons from glucose oxidase-mediated cell death (Scapagnini et al., 2006). Curcumin and its constituents induced HO-1 expression in MIN6 cells, a mouse β pancreatic cell line. The induction of HO-1 by curcumin is influenced by transcription factor Nrf2 and phosphotidylinositol 3-kinase (P13-kinase)/Akt-mediated signaling. Curcumin also augmented the mRNA levels of two important phase 2 enzymes: GCLM and NQO1, which are involved in the synthesis of glutathione and detoxification of quinones respectively (Pugazhenthi et al., 2007).

2.3 DNA-protective properties

Curcumin at low doses (up to 5 µg/mL) is anti-genotoxic but at high doses (more than 8 µg/mL) can cause genotoxicity (Antunes et al., 1999; Cao et al., 2007; Mendonca et al., 2009). Curcumin (10 µg/mL) induced mutagenic changes and potentiated doxorubicin and gamma radiation-mediated chromosomal aberrations in Chinese hamster ovary cells (Antunes et al., 1999; Araujo et al., 1999). Curcumin alone at 8 and 16 µg/mL enhanced micronucleus (MN) formation and at doses higher than 8 µg/mL amd increased the frequency of chromosomal
aberrations in human hepatoma G2 (HepG2) cells. On the contrary, pre-treatment of curcumin at a low dose (2 µg/mL) significantly decreased the cyclophosphamide (CPA)-induced MN formation in HepG2 cells (Cao et al., 2007). Pre-treatment of curcumin at low concentrations (1-5 µg/mL) alleviated the increased frequency of MN induced by cisplatin (cDDP) in PC12 cells but at high dose (10 µg/mL, alone) it significantly augmented the MN frequency. At doses greater than 16 µg/mL, curcumin caused a reduction in cell viability (Mendonca et al., 2009). Ingestion of a curcumin containing diet ameliorated DNA damage in a transgenic mouse model of Alzheimer’s disease (AD) showing a 10 fold reduction in buccal MN frequency. Furthermore, these AD mice had a 2 fold increase in buccal cell and brain telomere length compared to AD control group (Thomas et al., 2009).

3 Resveratrol

Resveratrol (3, 4’, 5-trihydroxystilbene, Fig. 1) is a white powder with yellow cast and a polyphenolic phytoalexin found in grapes, red wine, mulberries, pines, peanuts, and other plant derived products (Burns et al., 2002; Delmas et al., 2006; Ibern-Gomez et al., 2000). Resveratrol has two phenolic rings linked by a styrene double bond and it exists in two isoforms, trans and cis. The trans-isomer is more stable than cis-isomer (Shakibaei et al., 2009). Table 2 summarises findings of the most important investigations presented in this section.

3.1 Anti-inflammatory effects

Resveratrol is a potent inhibitor of inflammatory molecules. The anti-inflammatory properties of resveratrol are associated with inhibition of NF-kappa B in LPS-, TNF-α-, or PMA-mediated macrophages, dendritic, myeloid (U-937), Jurkat, and epithelial (HeLa) cells (Gao et al., 2001;
Manna et al., 2000). Resveratrol inhibits NF-kappa B activation by inhibiting IκB kinase (Holmes-McNary and Baldwin, 2000). Resveratrol also inhibits the expression of iNOS and COX-2 in cytokine (TNF-α, IL-1β, or IFN-γ)-stimulated human primary airway epithelial cells (Donnelly et al., 2004) and blocks COX-2 transcription in PMA-stimulated human mammary epithelial cells (Subbaramaiah et al., 1998). Resveratrol significantly suppresses the secretion of TNF-α and nitric oxide in LPS-stimulated rat cortical microglia and N9 microglial cells (Bi et al., 2005) and also inhibits the production of TNF-α, IL-1, IL-6, IL-12 and IFN-γ by splenic lymphocytes and macrophages (Gao et al., 2001; Kowalski et al., 2005). Resveratrol also exhibits strong anti-inflammatory activity in in vivo C5 anaphylatoxin (C5a)-mediated inflammation (Issuree et al., 2009). Pre-incubation with resveratrol (10-40 µM) abrogated the release of inflammatory cytokines (TNF-α, IL-1β, IL-6, and MIP-1α) from C5a-stimulated human and mouse neutrophils. Further, resveratrol treatment inhibited C5a-induced oxidative burst (superoxide anion production), release of β-glucuronide (responsible for neutrophil degranulation) and ERK-phosphorylation (Issuree et al., 2009). Additionally, resveratrol inhibits C5a-stimulated neutrophil migration/recruitment, and production of inflammatory cytokines in a mouse model of C5a-induced acute peritonitis (Issuree et al., 2009).

Resveratrol shows inhibitory effects on the expression of cell adhesion molecules. Resveratrol attenuated the IL-6 induced expression of ICAM-1 in endothelial cells (ECs; Wung et al., 2005) and also inhibited Porphyromonas gingivalis LPS-induced endothelial dysfunction in human microvascular endothelial cells (HMECs; Park et al., 2009). Furthermore, it blocked the expression of adhesion molecules, ICAM-1 and VCAM-1 on HMECs by inhibiting NF-kappa B activation (Park et al., 2009).
3.2 Cyto-protective effects

A growing body of research show that resveratrol exerts potent cyto-protective activity. Resveratrol incubation protected cultured hippocampal neurons from NO induced neurotoxicity (Bastianetto et al., 2000). The addition of resveratrol (15-40 µM) to rat hippocampal cells abolished β-amyloid-induced toxicity through activation of protein kinase C (Han et al., 2004). In mid-brain slice cultures, concurrent treatment of resveratrol with neurotoxins such as 1-MPP⁺, sodium azide, thrombin, and N-methyl-N'-nitro-N-nitroguanidine (MNNG) significantly protected dopaminergic neurons from these neurotoxins. In addition, resveratrol inhibited the MPP⁺-induced glutathione depletion and suppressed the MNNG-induced release of acetylated P53 levels (Okawara et al., 2007).

Incubation of rat aortic smooth muscle cells (ASMCs) with resveratrol at 25, 50, and 100 µM for 24, 48, and 72 h significantly increased cellular antioxidants and phase II enzymes including superoxide dismutase (SOD), catalase, GSH, glutathione reductase (GR), glutathione peroxidase (GPx), glutathione S-transferase (GST), and NAD(P)H:quinone oxidoreductase-1 (NQO1) in a concentration and/or time-dependent fashion (Li et al., 2006). Resveratrol also elevated the mRNA levels of catalase, GSTA1, and NQO1. Moreover, pre-treatment with resveratrol protected against xanthine oxidase (XO)/xanthine induced cytotoxicity, increasing cell viability and reducing the intracellular accumulation of reactive oxygen species (Li et al., 2006). Resveratrol treatment also prevents apoptosis in embryonic rat cardiomyocytes exposed to ischemia. The anti-apoptotic effect of resveratrol in cardiomyocytes is mediated by the sirtuin 1-forkhead transcription factor 1 (SIRT1-FOXO1) pathway. The exposure of cardiomyocytes to resveratrol (20 µM) under ischemic conditions elevated the expression of SIRT1 but reduced the
expression of FOXO1 (Chen et al., 2009). SIRT1 is responsible for cell defense and survival in response to oxidative stress (Brunet et al., 2004; Motta et al., 2004). FOXOs mediate the transcription of genes involved in the oxidative stress response, DNA-repair, cell cycle arrest, and apoptosis (Birkenkamp and Coffer, 2003; Van Der Heide et al., 2004). SIRT1 differentially affects FOXOs functions, stimulating FOXOs effects on cell cycle arrest and expression of DNA-repair genes but inhibiting FOXOs effects on apoptosis in the presence of stress stimuli. Therefore, decreased FOXO1 expression by resveratrol under ischemic conditions is mediated by activation of SIRT1 (Chen et al., 2009), leading to cyto-protection.

Epidemiological studies show that consumption of a resveratrol rich diet is related to a reduction in the risk of cardiovascular diseases in segments of the French population. This is despite of their regional consumption of high fat and high cholesterol diets and smoking habits and is referred to as the phenomenon of the French paradox (Gordon, 1996; Renaud and de Lorgeril, 1992). Resveratrol is effective against *in vivo* and *in vitro* cigarette smoke-induced vascular oxidative stress and inflammation and prevents smoking-induced expression of reactive oxygen species and inflammatory markers such as ICAM-1, iNOS, TNF-α, IL-1 β, IL-6, NF-kappa B in rat arteries and cultured coronary arterial endothelial cells (CAECs; Csiszar et al., 2008). These protective effects of resveratrol are mediated through the activation of SIRT1. In addition, resveratrol significantly protected endothelial cells against cigarette smoke extract-induced DNA damage (Csiszar et al., 2008). Resveratrol (40 µM) also protects HepG2 cells from triglyceride accumulation induced by a high fat diet (palmitate) by enhancing the expression of SIRT1 and FOXO1 and reducing sterol regulatory element binding protein1 (SREBP1) expression (Wang et al., 2009). Pre-treatment of resveratrol rescued the rat endothelial cells and arteries against TNF-α, ox-LDL, and H₂O₂-induced apoptotic cell death via inhibition of caspase-3/7 activity and

12
elevation of antioxidant enzymes (catalase and GPx). Resveratrol also has been shown to attenuate UV-induced DNA damage (Ungvari et al., 2007). Dietary administration of resveratrol (1 mg/kg/day) to rats prior to or with dextran sulphate sodium (DSS; induces intestinal inflammation, diarrhea and bloody stools) for 20 days ameliorated DSS-induced symptoms such as colon shortening, degradation of colon wall structure and changes in haematological parameters (lower levels of red blood corpuscles (RBCs), haemoglobin (Hb), haematocrit (HCT)). Additionally, DSS-stimulated an increase in COX-2, NO, prostaglandins, and prostaglandin E synthase protein (PTGES) levels in the colonic mucosa, which was reduced by resveratrol treatment (Larrosa et al., 2009).

Oral administration of resveratrol to streptozotocin (STZ) treated rats led to significant decrease in blood glucose level and improved myocardial function. Resveratrol exerted angiogenic actions by enhancing the expression of HO-1, thioredoxin (Trx-1), vascular endothelial growth factor (VEGF), and endothelial nitric oxide synthase (eNOS). Additionally, resveratrol protects cardiomyocytes from ischemia/reperfusion injury through an increase in MnSOD activity (Thirunavukkarasu et al., 2007). Resveratrol also induces the expression of HO-1 in a concentration-dependent manner. Treatment of human ASMCs with low concentrations (≤ 10 mM) of resveratrol increased HO-1 expression and promoter activity whereas higher concentrations (≥ 20 mM) of resveratrol showed the reverse. Resveratrol appears to regulate HO-1 induction through the NF-kappa B pathway. At low concentrations (1-10 mM) resveratrol enhanced the NF-kappa B binding activity, however, concentrations greater than 20 mM blocked the NF-kappa B binding activity (Juan et al., 2005).
3.3 DNA-protective effects

Concurrent treatment of resveratrol with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) or estradiol exposed MCF-10 F cells inhibited the estrogen metabolism and DNA-adduct formation. TCDD-induced expression of CYP1B1 was decreased in the presence of resveratrol (Lu et al., 2008). Benzo(α)pyrene induced sperm DNA damage and cell death which were prevented by concomitant treatment with resveratrol. Resveratrol inhibited the BaP-diol-epoxide (BPDE) adduct formation in sperm DNA and apoptotic and necrotic cell death (Revel et al., 2001). In another study, daily oral administration of resveratrol (8 mg/kg) with 1, 2-dimethylhydrazine (DMH) for 30 weeks protected rat leukocytes from DMH-induced DNA damage and oxidative stress, decreasing comet attributes and up-regulating the level of antioxidant enzymes (catalase, SOD, GR, GPx, and GST (Sengottuvelan et al., 2009). Formation of ROS may contribute to DNA damage, which is typified by the release of base oxidation products. 8-oxo-7,8-dihydro-2'-deoxyguanosine (oxo8dG) is one of the base oxidation products, resulting from C-8 hydroxylation of guanine residues. The ratio of oxo8dG to an undamaged nucleoside, deoxyguanosine, is a biomarker for oxidative DNA damage (Floyd, 1990). Resveratrol protected from potassium bromate (KBrO3; renal carcinogen that promotes free radical formation) induced DNA damage by decreasing the level of kidney oxo8dG (Cadenas and Barja, 1999). Resveratrol also inhibited advanced glycation end-product (AGEs; promotes free radical formation)-induced oxidative DNA damage, decreasing the level of vascular smooth muscle cell (VSMC) oxo8dG in stroke-prone rats (Mizutani et al., 2000). However, combined treatment of resveratrol with UVA
exposure promoted the formation of oxo8dG, DNA strand breaks and cell death in HaCa T human keratinocytes (Seve et al., 2005).

4 Flavonoids

Flavonoids are ubiquitous polyphenolic compounds comprised of several classes including flavonols, flavanones, flavanols, isoflavones and flavans (Manach et al., 2004). Many flavonoids possess anti-inflammatory, anti-viral, antioxidant and anti-carcinogenic properties (Di Carlo et al., 1999; Middleton et al., 2000; Riboli and Norat, 2003). Table 3 summarises findings of the most important investigations discussed in this section.

4.1 Anti-inflammatory effects

Apigenin (4’, 5, 7-trihydroxyflavone) is found in parsley and celery and possessed strong anti-inflammatory effects. Apigenin down-regulated the expression of IL-1β and TNF-α in LPS-stimulated mouse macrophages and human monocytes (Kowalski et al., 2005; Nicholas et al., 2007). Moreover, pre-treatment with apigenin before LPS exposure significantly mitigated serum TNF levels and protected mice from LPS-induced toxicity. Apigenin also blocked the secretion of IL-8 in LPS-stimulated cells (Nicholas et al., 2007). Apigenin has been reported as the most potent inhibitor of COX-2 and iNOS expression in LPS-stimulated mouse macrophages (Liang et al., 1999) and suppresses inflammatory responses through inactivation of NF-kappa B (Liang et al., 1999; Nicholas et al., 2007). It also attenuates neutrophil and lymphocyte adhesion to endothelial cells and adhesion of monocytes to HUVECs, by regulating the expression of ICAM and VCAM (Gerritsen et al., 1995; Lee et al., 2007).
Genistein (4', 5, 7-Trihydroxyisoflavone; Fig 1) is found in soybean and related products. Genistein suppressed LPS-induced TNF-α and IL-6 production in mouse macrophages (Calixto et al., 2004) and blocked the secretion of TNF-α and IL-1β in phytohemagglutinin-stimulated macrophages (Kesherwani and Sodhi, 2007). LPS-induced expression of COX-2 and iNOS by mouse macrophages was down-regulated by genistein treatment (Liang et al., 1999).

Other flavonoids such as luteolin, kaempferol, and quercetin (see Fig. 1) also have demonstrated anti-inflammatory potential. Luteolin (3', 4', 5, 7-tetrahydroxyflavone) isolated from Lonicera japonica inhibited the LPS induced release of TNF-α, IL-6, and NO by macrophages (Park et al., 2005; Xagorari et al., 2001). Luteolin, at 5-25 µM, significantly decreased the LPS-induced secretion of INF-γ, IL-6, COX-2, and iNOS in alveolar macrophage and peripheral macrophage RAW 264.7 cell lines. This anti-inflammatory action was accompanied by the suppression of NF-kappa B, IκB degradation, and AP-1 in LPS-activated macrophages (Chen et al., 2007). Luteolin inhibits carrageenan-induced paw oedema in rats receiving luteolin orally. Moreover, luteolin at 10 and 50 mg/kg significantly blocked COX-2 expression (Ziyan et al., 2007). Luteolin suppressed PMA-induced oedema in mice and also reduced the LPS-induced expression of ICAM-1 (Calixto et al., 2004).

Kaempferol (3’, 4’, 5, 7-tetrahydroxyflavone) and quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone) are flavonols, commonly found in broccoli, tea, onions, apples, and leafy green vegetables. Kaempferol at 5, 10, and 20 µM inhibited the TNF-α-induced production of IL-6 in mouse osteoblasts in a dose-dependent manner (Pang et al., 2006). Kaempferol and quercetin have been reported to reduce the activity of iNOS and COX-2 by suppressing the signalling of STAT-1, NF-kappa B and AP-1 in LPS- or cytokine-stimulated macrophages and HUVECs (Crespo et al.,
2008; Hamalainen et al., 2007). Strong inhibitory effects on adhesion molecules (VCAM, ICAM-1, and E-selectin) expression were observed in kaempferol treated human endothelial cells (Crespo et al., 2008). Quercetin attenuated the expression of pro-inflammatory cytokines in PMA and calcium ionophore (PMACI)-stimulated mast cells and suppressed the TNF-α induced recruitment of NF-kappa B to pro-inflammatory gene promoters in murine epithelial intestinal cells (Park et al., 2008; Ruiz et al., 2007). Quercetin reduced the PMA- or TNF-α-mediated expression of ICAM-1 in human endothelial cells (Kobuchi et al., 1999). Kaempferol and quercetin also inhibit LPS-induced nitrite oxide and NF-kappa B production in mice (Liang et al., 1999).

4.2 Cyto-protective effects

Flavonoids enhance survival against cytotoxic compound exposure. Pre-incubation of cardiomyocytes with flavonoids abolished doxorubicin-induced oxidative stress (Psotova et al., 2004). Pre-treatment with genistein afforded a marked protection against IL-1β and IFN-γ-mediated cytotoxicity in rat insulinoma cells (RINm5F) and rat pancreatic islets. Genistein inhibits cytokine-induced cell death, NO production, iNOS expression, and NF-kappa B through the suppression of extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. Genistein also blocked the cytokine-induced phosphorylation of STAT proteins (Kim et al., 2007). Epidemiological research suggests that consumption of soy containing foods may reduce the risk of breast cancer (Messina et al., 1994). Experimental studies have found that the soy isoflavone genistein is in part responsible for cancer prevention because of its strong affinity for oestrogen receptors (ERs; Messina et al., 1994). Genistein competes with oestrogens in binding estrogens receptors (ERs) and regulates oestrogen-regulated gene expression (Markiewicz et al., 1993).
Genistein also acts synergistically with tamoxifen (TAM) (chemotherapeutic for oestrogen receptor positive (ER\(^+\)) breast cancer; (Fisher et al., 1996)) in treating breast cancer. Genistein alone or with TAM inhibited the growth of ER\(^+\)/HER2 (human epidermal growth factor receptor2)-overexpressing BT-474 human breast cancer cells. The HER2 gene is associated with TAM resistance (Mai et al., 2007). Genistein (3.125, 6.25, 12.5, and 25 µM) treatment increased the cell population in the G1 phase. The combination of genistein and TAM showed even greater G1 arrest. DNA ladder (characteristic of apoptosis) formation was observed in BT-474 cells following genistein or the genistein and TAM combination. The inhibition apoptotic protein, also named survivin, was down-regulated by the combined treatment of genistein and TAM in both its mRNA and protein expression. Therefore, supplementation of genistein with TAM may improve the efficacy of TAM on prevention and/or treatment of ER\(^+\) and HER2-overexpressing breast malignancies (Mai et al., 2007). Apart from being an estrogen receptor agonist, genistein also inhibits tyrosine kinase activity via interaction with its ATP-binding site (Akiyama et al., 1987). That tyrosine kinase activity is greater in smooth muscle than in skeletal or cardiac muscle suggests that tyrosine kinases regulate smooth muscle contraction, cellular growth, proliferation, and secretory activities (Di Salvo et al., 1997). Injection of ovariectomized spontaneously hypertensive rats (SHR; estrogen deficient) with a low-dose (2.5 mg/kg) of genistein for two days reduced renal artery contraction and aortic tyrosine phosphorylation (Nevala et al., 2002). However, daily administration of the same dose for two weeks showed no effect. Further, both treatment regimes attenuated angiotensin II and noradrenaline-induced smooth muscle contraction in rats (Nevala et al., 2002). Angiotensin II stimulation activates tyrosine kinases such as focal adhesion kinases, janus kinases, the receptor kinases, epidermal growth factor and platelet derived-growth factor. Therefore, angiotensin II-regulated tyrosine
kinases seem to be required for angiotensin II-mediated vasoconstriction (Berk, 1999). The noradrenaline-induced contractions activate tyrosine kinases in rat aortic (Abeb e and Agrawal, 1995) and pulmonary artery smooth muscle (Savineau et al., 1996) in vitro. Thus, inhibition of angiotensin II and noradrenaline by the low-dose genistein treatment for two days may be due to inhibition of tyrosine kinases by genistein (Nevala et al., 2002). Genistein at a higher concentration (> 1 µM) binds to and transactivates peroxisome proliferator-activated receptor (PPAR)-gamma (transcriptional factor for adipogenesis; (Dang et al., 2003). Incubation with genestein shows biphasic effects on osteogenesis and adipogenesis in KS483 and mouse bone marrow cells. Genestein at 0.1-10 µM stimulates alkaline phosphate (ALP) activity, nodule formation, and catalase deposition (characteristics of osteogenesis), while at concentrations of >25 µM showed the reverse. Incubation with genestein (0.1-1 µM) decreased the number of adipocytes, while a concentration >10 µM stimulated adipogenesis (Dang et al., 2003). It is suggested that at lower concentration, genistein has ER-dependent effects on osteogenesis and adipogenesis but at higher concentrations, genistein has an anti-estrogenic effect due to activation of PPAR-gamma (Dang et al., 2003).

Flavonoids such as (-)-epigallocatechin gallate and quercetin protect human umbilical vein endothelial cells (HUVEC) from Cu²⁺-oxidized LDL and H₂O₂-induced cytotoxicity. These flavonoids attenuated oxidative stress-induced apoptosis, nuclear condensation and fragmentation, expression of Bax-2 and caspase-3 cleavage but restored the expression of Bcl-2 protein in endothelial cells (Choi et al., 2003; Jeong et al., 2005). Supplementation of quercetin to peritoneal dialysis fluid treated mesothelial cells blocked the LDH release and restored the cell viability (Riesenhuber et al., 2007). Pre-treatment with quercetin protected the rat pancreas in response to STZ administration. The STZ-mediated increase in NO level, malondialdehyde
(MDA), and decrease in antioxidant enzyme activity were prevented by daily treatment with quercetin (15 mg/kg/day) for 4 weeks (Coskun et al., 2005).

Flavonoids may act as pro-oxidants at increased concentrations. Quercetin at concentrations ≥100 µM cause cytotoxicity in rat aortic smooth muscle cells, producing reactive oxygen species, inducing apoptosis, increasing the phosphorylation of the p38 and JNK pathway, and enhancing the binding activity of NF-kappa B (Shih et al., 2004).

Flavonoid mediated cytoprotection is purportedly due to the induction of HO-1. Kaempferol and quercetin inhibit LPS-mediated inflammatory signals in RAW 264.7 cells by inducing HO-1 expression. The cytoprotective effects of flavonoids were inhibited by pre-treatment of the cells with tin protoporphyrin, a HO inhibitor. Additionally, the flavonoid treated cells showed an increase in bilirubin production (Lin et al., 2003). Bilirubin, which is derived from biliverdin, is the end product of haem catabolism. Bilirubin is a potent antioxidant present in human extracellular fluid and may reduce the risk of cardiovascular disease (CVD) by delaying the copper induced oxidation of lipids (Bulmer et al., 2008). That flavonoids increase bilirubin production may suggest that their mechanism of protection is mediated via bilirubins antioxidant capacity. Kaempferol treatment provided protection to PC12 cells against low serum or serum deprivation-induced cell death. Pre-treatment of kaempferol abrogated H₂O₂-mediated oxidative stress by expressing an elevated level of HO-1 protein. The ERK pathway was activated in these kaempferol treated PC 12 cells (Hong et al., 2009). Quercetin abolished the H₂O₂-induced apoptotic changes, elevation in intracellular peroxide levels, phosphorylation of ERK, and expression of P⁵³ proteins in rat glioma C6 cells. In addition, quercetin supplementation also afforded a significant protection against chemical anoxia-induced cytotoxicity in C6 cells. The
cyto-protective effects of quercetin against $\text{H}_2\text{O}_2$ and chemical anoxia involve the induction of HO-1 (Chen et al., 2006b) with increased bilirubin production likely protecting against $\text{H}_2\text{O}_2$ mediated radical production (Bulmer et al., 2008; Bulmer et al., 2007). Concomitant exposure of quercetin with LPS or IFN-γ inhibited the expression of NO, iNOS, NF-kappa B, IκBα, AP-1, and STAT-1 in BV-2 microglia by inducing the HO-1 protein (Chen et al., 2005).

Apigenin exerted inhibitory effects on HO-1 protein activation. The administration of apigenin to mouse embryonic fibroblasts prevented the haemin-mediated HO-1 induction and activity and also decreased the basal level of HO-1 protein expression (Abate et al., 2005). Incubation of luteolin protected auditory cells from cisplatin-induced cell damage and abrogated cisplatin-induced cell death, elevated the expression of HO-1, and activated the ERK pathway (Choi et al., 2008).

4.3 DNA-protective properties

Administration of quercetin at 3, 6, 12, 24, and 48 µM to human peripheral blood lymphocytes (PBMCs) dose-dependently alleviated DNA damage in response to gamma radiation. Gamma radiation-elicited DNA strand breaks, MN frequencies, comet attributes, and the levels of thiobarbituric acid reactive substances (TBARS) were suppressed by pre-treatment with quercetin. Additionally, quercetin treatment prior to radiation exposure elevated the levels of antioxidant enzymes such as GHS, SOD, CAT, and GPx (Devipriya et al., 2008). Quercetin and quercetin-rich juice treatment prior to $\text{H}_2\text{O}_2$ and BoP challenge protected the human lymphocytes both in in vivo and in vitro by abolishing oxidative DNA damage and the formation of BPDE-
DNA adducts (Wilms et al., 2005). Grape seed extract diets containing gallic acid, catechins, epicatechin and proanthocyanidins also protect AD mice from DNA damage by reducing the MN frequency (10 fold) and increasing the buccal cell telomere length (2 fold; Thomas et al., 2009).

Flavonoids may also contribute to DNA damage. Incubation with kaempferol (100 µM) for 90 min decreased ROS levels in HL-60 cells, however, increased the number of DNA strand breaks. Kaempferol did not increase the level of oxidized DNA purines, therefore, kaempferol-induced DNA damage could be mediated by highly localised changes in ROS generation that do not lead to a general increase in oxidative stress. Hydroxyl radical formation (HO\(^\cdot\)) close to DNA molecules may initiate strand breakage (Bestwick et al., 2005). Kaempferol elevates HO\(^\cdot\) generation in the presence of ferric-EDTA chelate. When citrate and ascorbate were used and iron chelates, kaempferol had little or no effect on HO\(^\cdot\) formation. Therefore, kaempferol shows adverse effects on DNA integrity despite reducing ROS levels (Bestwick et al., 2005). Kaempferol (10-100 µM) promoted DNA damage and lipid peroxidation in a concentration-dependent manner in rat liver nuclei, which was stimulated by the presence of ferric (Fe(III)) and Cu(II) ions (Sahu and Gray, 1994). Both quercetin and luteolin can induce DNA cleavage and form DNA ladders. Quercetin induces DNA damage, enhancing the formation of 8-hydroxydeoxyguanosine (8-OHdG), an indicator of oxidative DNA damage in HL-60 cells. On the contrary, luteolin reduced topoisomerase II (topo II) activity of nuclear extract and cleaved DNA by forming a luteolin-topo II-DNA ternary complex (Yamashita and Kawanishi, 2000).
5 Bioavailability

Although polyphenols are important constituents in the human diet they show poor bioavailability. Once absorbed by the intestine, polyphenols are distributed into the body’s tissues and metabolized/excreted by the liver. Only a few studies have reported data on polyphenol concentration in human tissues. Most polyphenols are rapidly metabolised (sulphation, methylation, and glucuronidation) and excreted by the liver, therefore, tissue concentrations remain low. Metabolites of polyphenols are excreted into the urine and bile (Manach et al., 2004).

The absorption, metabolism, and tissue distribution of curcumin has been studied in in vivo studies. Approximately 60 and 75% of curcumin was excreted in the faeces of rats receiving curcumin orally (400 mg, 1 g/kg respectively). Only traces of curcumin were found in portal blood (< 5 µg/mL) and in the liver and kidney (<20 µg/tissue; Ravindranath and Chandrasekhara, 1980; Wahlstrom and Blennow, 1978). Curcumin and its metabolites (curcumin glucuronide or curcumin sulphate) showed variation in their distribution into the plasma and colonic mucosa depending their mode of administration. Following i.g. administration of curcumin (500 mg/kg), the plasma levels of curcumin were ~3 to 5 times higher in rats than in those that received curcumin (2 % in diet for 3 h) orally (Sharma et al., 2001). Furthermore, LC-MS/MS analysis of rat plasma revealed a low maximum plasma concentration ($C_{\text{max}}; 0.06 \pm 0.01 \mu g/ml$) after oral administration (500 mg/kg) compared to i.v. administration of curcumin (10 mg/kg; $0.36 \pm 0.05 \mu g/ml$). Blood samples were collected at 10-50 min and 1-3 h after dosing. Curcumin was metabolised rapidly after oral administration with a half-life $28.1 \pm 5.6$ and $44.5 \pm$
7.5 min for p.o. and i.v. administration respectively and showed 1% oral bioavailability (Yang et al., 2007).

Estimations of curcumin bioavailability in humans are rare. In one study, oral administration of curcumin at 4, 6, and 8 g/day in 25 patients with precancerous lesions yielded plasma curcumin concentrations of 0.19, 0.20, and 0.60 µg/mL, respectively. No metabolites of curcumin were detected in the study (Cheng et al., 2001). Another study was conducted in six patients with advanced colorectal cancer. The ingestion of curcumin at 3.6 g daily for up to three months yielded glucuronides and sulphates of curcumin and desmethoxycurcumin in plasma. Curcumin and its conjugates were also detected in urine samples of all six patients. The urinary levels varied between 0.1 and 1.3 µM (curcumin), 19 and 45 nM (curcumin sulphate), 210 and 510 nM (curcumin glucuronide; Sharma et al., 2004). The bioavailability of curcumin has also been studied in 12 healthy human volunteers who were given curcumin orally in a single dose of 10 or 12 g. The maximum concentrations of curcumin glucuronide and curcumin sulphate at the 10 g dose were 2.04 ± 0.31µg/L and 1.06 ± 0.40 µg/L respectively, and at 12 g/L were 1.40 ± 0.74 µg/L and 0.87 ± 0.44 µg/L, respectively (Vareed et al., 2008).

The absorption and metabolism of resveratrol have been shown in in vitro studies utilising an isolated rat small intestine perfusion model. Forty-six percent of resveratrol was excreted by the small intestine, 21% was absorbed into the vascular compartment and 2 % appeared in the intestinal tissue (Andlauer et al., 2000). In another study, the absorption and metabolism of resveratrol across the jejunum and ileum were measured. Very little resveratrol was absorbed intact (0.3 nmol/cm jejunum). The major compound detected on the serosal side of jejunal enterocytes was the glucuronide conjugate of resveratrol (96 % of the amount absorbed),
indicating the ready metabolism of this compound (Kuhnle et al., 2000). The *in vitro* metabolism and stability of resveratrol was studied after incubation of resveratrol (0.1 mM) with human hepatocytes for 4 h. LC-UV-MS/MS showed three resveratrol glucuronide peaks, resveratrol-4-glucuronide, resveratrol-3-glucuronide, and cis-resveratrol-4-glucuronides (Yu et al., 2002).

The bioavailability of resveratrol has also been studied in *in vivo* rodent and human models also. Resveratrol is rapidly absorbed and reaches its highest concentration in the liver and kidney after 60 min in rats that were administered 4 mL of red wine (corresponding to 86 µg/kg resveratrol) (Bertelli et al., 1996). After receiving resveratrol (20 mg/kg, i.p.), rat hepatocytes produced resveratrol glucuronide and resveratrol sulphate as two major metabolites of resveratrol. These two metabolites were also detected in the urine. Similar metabolite peaks were found in mouse serum samples, when resveratrol was administered at two different doses of 20 and 60 mg/kg i.p. or i.g. (Yu et al., 2002).

The absorption of resveratrol in humans was first conducted in 12 healthy human males who were given 25 mg/70 kg resveratrol, orally. The highest concentration of resveratrol was achieved in serum after 30 min and 17% was excreted in the urine after 24 h (Goldberg et al., 2003). In another study, oral administration of 25 mg of 14C labelled resveratrol (110 µmol) to human subjects showed that resveratrol is rapidly absorbed in plasma with peak plasma levels of resveratrol 491 ± 90 ng/mL. Both sulphate and glucuronide conjugates of resveratrol were detected in urine and plasma, however, only traces of unchanged resveratrol were detected in plasma (Walle et al., 2004).

The absorption and metabolism of quercetin is well understood among the flavonoids. Administration of a quercetin containing diet (50 or 500 mg/kg) to rats for 11 weeks resulted in a
wide distribution of quercetin metabolites in the body tissues. A quercetin diet (500 mg/kg) administered to pigs for three days revealed quercetins in tissues including the liver and kidneys (de Boer et al., 2005). Plasma quercetin concentrations were first observed in 27 healthy human volunteers who consumed four quercetin capsules (each containing 250 mg quercetin, 50 mg rutin, and 250 mg other bioflavonoids) daily for 28 days. At day 0 (pre-supplementation), quercetin was essentially undetectable (0.10 ± 0.09 µM). The plasma quercetin concentrations then increased from 0.10 ± 0.09 µM to 1.5 ± 0.3 µM after 28 days (Conquer et al., 1998). In another study, three doses of quercetin (8, 20, and 50 mg) were administered orally to 16 human subjects. Quercetin was detected in plasma as the glucuronide, sulphate and as the unconjugated form. The volunteers also showed a dose dependent increase in the C$_{max}$ value (0.14, 0.22, 0.29 µM; Erlund et al., 2000). Isoflavones show higher plasma concentrations after oral administration. The isoflavone genistein induced a higher plasma concentration (341 ± 74 ng/mL) than daidzein (isoflavone; 194 ± 30.6 ng/mL) in women who were administered a single bolus dose (50 mg) of each isoflavone (Setchell et al., 2001).

The health effects of polyphenols depend on their dietary intake and bioavailability, which show great variation. Dietary consumption of turmeric up to 150 mg/day shows no adverse effects in humans. The intake of curcumin up to 350 mg/kg body weight for 3 months was not harmful in rats, dogs or monkeys (Sharma et al., 2005). Half-life values for curcumin administration are 28 and 44 min for p.o. and i.v. administration, respectively (Yang et al., 2007). Resveratrol at concentrations and doses ranging from ~32 nM - 100 µM and ~100ng - 1,500 mg/kg body weight have been widely used in in vitro and in vivo studies and show very short half life (8-14 min; Baur and Sinclair, 2006). The elimination of quercetin and isoflavones are slow with half-lives in the order of 11 to 28h and 4-8h, respectively (Manach et al., 2004). The distribution
of polyphenols into body tissues varies depending on their mode of administration. The oral bioavailability of polyphenols ranges from 2-20% (Hu, 2007).

6 Conclusion

The present review discusses the anti-inflammatory, cyto-and DNA protective effects of dietary polyphenols, including curcumin, resveratrol, and flavonoids. Curcumin (turmeric), resveratrol (wines and berries), and flavonoids (fruits and vegetables) induce potent anti-inflammatory effects, protecting cells and DNA from stress-mediated injury.

Curcumin shows a myriad of anti-inflammatory activities in in vitro studies in response to various stressors. Curcumin's anti-inflammatory effects are attributed to its inhibition of cell adhesion molecule, NF-kappa B and AP-1 expression. In vitro studies show that curcumin protects from oxidative stress by preventing the release of free radicals. Curcumin also elevates the expression of MKP-1, which inhibits MAPKs activation during stress conditions. In vivo, the administration of curcumin attenuates inflammation in various clinical trials (Jurenka, 2009). Curcumin is a potent activator of HO-1 mRNA and protein expression via the Nrf2 transcription factor. Curcumin also enhances the expression of phase II enzymes and exerts a biphasic effect on DNA damage, protecting DNA at low doses (1-5 µg/ml) but promoting it at higher doses (>8 µg/ml).

Resveratrol also possesses anti-inflammatory activities both in in vitro and in vivo studies, inhibiting the release of inflammatory cytokines, activation of transcription factors NF-kappa B, cell adhesion molecules and ERK-phosphorylation. In vitro incubation with resveratrol affords protection against NO, neurotoxin, xanthine oxidase and ischemic stress. Resveratrol induces
cyto-protective effects by activating the SIRT1 (responsible for cell defense and cell survival during oxidative stress) transcription factor and elevating the levels of phase II enzymes. In vivo administration of resveratrol protects from DSS-induced colitis and streptozotocin-induced cardiac dysfunction in rats. Pre-treatment with resveratrol protects rats from cigarette smoke-induced oxidative stress and inflammation. Resveratrol shows a dose-dependent effect on HO-1 activation, inhibiting expression at low concentrations (1-10 mM) but elevating it at high concentrations >20 mM. Resveratrol reduces DNA damage from TCDD, benzo(α)pyrene, DMH, KBrO₃, and AGEs decreasing DNA-adduct formation, levels of oxo8dG, comet attributes and necrotic cell death. However, resveratrol can promote DNA damage in the presence of UVA radiation, increasing the formation of oxo8dG.

Flavonoids are a family of compounds including flavonols, flavanones, flavanols, isoflavones, and flavans. The present review focuses primarily on apigenin, genistein, luteolin, kaempferol and quercetin, all of which strongly inhibit inflammatory responses. Genistein possess strong cyto-protective activity, inhibiting cytokine-mediated toxicity, breast cancer and promoting chemotherapeutic efficacy. Genistein’s mechanisms of action include inhibition of tyrosine kinases, activation of PPAR-gamma and binding of oestrogen receptors. Kaempferol, quercetin, and luteolin also afford protection against oxidative stress by inducing the expression of HO-1, however, apigenin inhibits HO-1 induction. Quercetin ameliorates DNA damage resulting from gamma radiation, reducing DNA strand breaks, MN formation, comet attributes, and levels of reactive oxygen species. Quercetin administration, both in in vivo and in vitro, prevents H₂O₂, and benzo(α)pyrene-induced DNA damage. Flavonoids can also induce DNA damage. For example, in the presence of transition metals, kaempferol promotes DNA damage and lipid
peroxidation. Quercetin and luteolin have also been shown to induce DNA cleavage and ladder formation in HL-60 cells.

A vast number of in vitro and laboratory animal studies and some in vivo studies show polyphenols induce cytoprotective responses/mechanisms against various environmental toxins and could prevent disease. Therefore, natural product based therapy could be a promising preventative/treatment for chronic diseases. However, currently, more evidence is required so that the aforementioned plant extracts can be used as cytoprotective agents in human population studies. Additionally, polyphenols exert dual effects with low doses protecting cells but inducing toxicity at high doses. Moreover, there is not sufficient data concerning the bioavailability of polyphenols in humans. Further research with the aim of determining the effects of polyphenols on stress-mediated responses should include human trials and the elucidation of their cytoprotective mechanism of action responsible for their pharmacological efficacy.

Conflict of interest

The authors declare no conflict of interest
References


by the inhibition of IkappaB kinase, nuclear factor-kappa B and STAT1, and depends on heme oxygenase-1 induction in mouse BV-2 microglia. Eur J Pharmacol 521, 9-20.


37


<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Dose/Concentration</th>
<th>Stimulation</th>
<th>Signalling pathways</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-inflammatory</td>
<td>10 µM</td>
<td>LPS, IFN-γ</td>
<td>Inhibits NO and iNOS secretion from RAW264.7 macrophages</td>
<td>(Brouet and Ohshima, 1995)</td>
</tr>
<tr>
<td></td>
<td>5-20 µM</td>
<td>Rat histocytoma (Ak-5)</td>
<td>Blocks the release of NO from peritoneal macrophages of AK-5 tumor bearing rats</td>
<td>(Bhaumik et al., 2000)</td>
</tr>
<tr>
<td></td>
<td>2-60 µM</td>
<td>TNF-α, PMA, H₂O₂</td>
<td>Inhibits NF-kappa B and IκBα in human myelomonoblastic cells</td>
<td>(Singh and Aggarwal, 1995)</td>
</tr>
<tr>
<td></td>
<td>25, 50 µM</td>
<td>None</td>
<td>Decreases NF-kappa B and AP-1 binding and expression in human glioma cells.</td>
<td>(Dhandapani et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>0.5-10 µM</td>
<td>PMA, LPS</td>
<td>Inhibits the release of Pro-inflammatory cytokines from human monocytes</td>
<td>(Abe et al., 1999)</td>
</tr>
<tr>
<td></td>
<td>12.5-30 µM</td>
<td>LPS, Con A,</td>
<td>Inhibits the expression of cytokines in murine lymphocytes and macrophages</td>
<td>(Gao et al., 2004)</td>
</tr>
<tr>
<td></td>
<td>1-25 µM</td>
<td>LPS</td>
<td>Down-regulates the cytokines expression from dendritic cells</td>
<td>(Kim et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>10-50 µM</td>
<td>TNF-α</td>
<td>Blocks expression of cell adhesion molecules</td>
<td>(Kumar et al., 1998)</td>
</tr>
<tr>
<td></td>
<td>20-80 mg/kg</td>
<td>Carrageen</td>
<td>Prevents oedema in rats</td>
<td>(Srivastava and Srimal, 1985)</td>
</tr>
<tr>
<td></td>
<td>0.1-1.0 µM</td>
<td>TPA</td>
<td>Inhibits epidermal inflammation in mouse</td>
<td>(Huang et al., 1991)</td>
</tr>
<tr>
<td></td>
<td>3-100 µM</td>
<td>AA</td>
<td>Prevents epidermal inflammation in mouse</td>
<td>(Huang et al., 1991)</td>
</tr>
<tr>
<td></td>
<td>1200 mg/day</td>
<td>Arthritis</td>
<td>Alleviates IBD-mediated inflammation</td>
<td>(Deodhar et al., 1980)</td>
</tr>
<tr>
<td></td>
<td>550 mg twice/day</td>
<td>IBD</td>
<td>Alleviates IBD-mediated inflammation</td>
<td>(Holt et al., 2005)</td>
</tr>
<tr>
<td>Cytoprotective</td>
<td>375 mg/day</td>
<td>Anterior uveitis</td>
<td>Improves visual acuity and aqueous flare, reduces keratic precipitates</td>
<td>(Lal et al., 1999)</td>
</tr>
<tr>
<td></td>
<td>200 mg/kg</td>
<td>Cerulean, ethanol</td>
<td>Protects from pancreatitis</td>
<td>(Gukovsky et al., 2003)</td>
</tr>
<tr>
<td></td>
<td>20 µM</td>
<td>Shiga toxin</td>
<td>Cell survival, DNA damage, HSP70 in HK-2 cells</td>
<td>(Sood et al., 2001)</td>
</tr>
<tr>
<td></td>
<td>12.5-100 µM</td>
<td>H₂O₂</td>
<td>Inhibits oxidative stress in NG108-15 cells</td>
<td>(Mahakunakorn et al., 2003)</td>
</tr>
<tr>
<td></td>
<td>50-200 nM</td>
<td>Ethanol</td>
<td>MAPK, MKP-1 in HT22 cells</td>
<td>(Pae et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>5-25 µM</td>
<td>Glucose oxidase</td>
<td>Protects rat astrocytes and neurons by elevating HO-1 and Nrf2 expression</td>
<td>(Scapagnini et al., 2006)</td>
</tr>
<tr>
<td>DNA-protective</td>
<td>1-5 µg/ml</td>
<td>CPA, cDDP</td>
<td>Alleviates MN formation, in HepG2 and PC12 cells telomere length</td>
<td>(Cao et al., 2007; Mendonca et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>0.07 % diet</td>
<td>AD</td>
<td>MN frequency, telomere length in mouse model of AD</td>
<td>(Thomas et al., 2009)</td>
</tr>
</tbody>
</table>

Abbreviations: AA, arachidonic acid; AD, alzheimer’s disease; ConA, Concanavalin A; CPA, cyclophosphamide; cDDP, cisplatin; IBD, inflammatory bowel disease; IFN-γ, interferon-gamma; H₂O₂, hydrogen peroxide; LPS, lipopolysaccharide; PMA, phorbol 12-myristate 13-acetate; TNF-α, tumor necrosis factor alpha; TPA, 12-O-tetradecanoylphorbol-13-acetate.
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Doses/Concentrations</th>
<th>Stimulation</th>
<th>Signaling pathways</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-inflammatory</td>
<td>6.25-50 µM</td>
<td>LPS</td>
<td>Inhibits NF-kappa B and cytokines expression in macrophages and splenocytes</td>
<td>(Gao et al., 2001)</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>TNF, LPS</td>
<td>Down-regulates the expression of NF-kappa B and IκB kinase in human monocytes and macrophages</td>
<td>(Holmes-McNary and Baldwin, 2000)</td>
</tr>
<tr>
<td></td>
<td>5 -25 µM</td>
<td>TNF, PMA</td>
<td>Inhibits activation of NF-kappa B in Jurkat, Hela, and myeloid cells</td>
<td>(Manna et al., 2000)</td>
</tr>
<tr>
<td></td>
<td>1,10, 100 µM</td>
<td>Cytokines</td>
<td>Blocks the release of iNOS and COX-2 in human primary airway epithelial cells</td>
<td>(Donnelly et al., 2004)</td>
</tr>
<tr>
<td></td>
<td>2.5, 10, 30 µM</td>
<td>PMA</td>
<td>Prevents COX-2 transcription in human mammary epithelial cells</td>
<td>(Subbaramaiah et al., 1998)</td>
</tr>
<tr>
<td></td>
<td>0.01-10 µg/mL</td>
<td>LPS</td>
<td>Down-regulates the release of NO and TNF-α in microglial cells</td>
<td>(Bi et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>50 µM</td>
<td>LPS</td>
<td>Inhibits secretion of cytokines from macrophages</td>
<td>(Kowalski et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>10, 20, 40 µM</td>
<td>C5 anaphylatoxin</td>
<td>Reduces the expression of cytokines, oxidative burst, β-glucuronide, ERK</td>
<td>(Issuree et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>1 or 10 µM</td>
<td>P.gingivalis LPS</td>
<td>Suppresses cell adhesion molecules in HUMECs</td>
<td>(Park et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>100 µM</td>
<td>IL-6</td>
<td>Down-regulates the expression of ICAM-1 in endothelial cells</td>
<td>(Wung et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>5-40 µM</td>
<td>β-amyloid</td>
<td>Activates protein kinase C</td>
<td>(Han et al., 2004)</td>
</tr>
<tr>
<td></td>
<td>10 30, 100 µM</td>
<td>Neurotoxins</td>
<td>↑GSH, ↓P5 expression in neurons</td>
<td>(Okawara et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>25, 50, 100 µM</td>
<td>XO/xanthine</td>
<td>↑phase II enzymes, ↓ROS generation in ASMCs</td>
<td>(Li et al., 2006)</td>
</tr>
<tr>
<td></td>
<td>20 µM</td>
<td>Ischemia</td>
<td>↑SIRT1, ↓FOXO1 in rat cardiomyocytes</td>
<td>(Chen et al., 2009)</td>
</tr>
<tr>
<td>Cytoprotective</td>
<td>25 mg/kg/day</td>
<td>cigarette smoke</td>
<td>Blocks the release of cytokines and ROS from rat arteries and CAECs</td>
<td>(Csizsar et al., 2008)</td>
</tr>
<tr>
<td></td>
<td>40 µM</td>
<td>palmitate</td>
<td>Elevates the expression of SIRT1 and FOXO1</td>
<td>(Wang et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>1-100 µM</td>
<td>TNF-α, ox-LDL, H₂O₂</td>
<td>Inhibits caspase-3/7 activity in rat endothelial cells and arteries</td>
<td>(Ungvari et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>1 mg/kg/day</td>
<td>DSS</td>
<td>Alleviates colon damage, blocks secretion of inflammatory molecules in rats</td>
<td>(Larrosa et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>2.5 mg/kg/day</td>
<td>STZ</td>
<td>Induces the expression of HO-1,Trx-1,VEGF,eNOS, and MnSOD in rats</td>
<td>(Thirunavukkarasu et al., 2007)</td>
</tr>
<tr>
<td>DNA protective</td>
<td>50 mg/kg/week</td>
<td>BaP</td>
<td>Prevents BPDE-DNA adduct formation and cell death in mouse</td>
<td>(Revel et al., 2001)</td>
</tr>
<tr>
<td></td>
<td>16mg/kg/day</td>
<td>KBrO₃</td>
<td>Decreases the level of oxo8dG in rat kidneys</td>
<td>(Cadenas and Barja, 1999)</td>
</tr>
<tr>
<td></td>
<td>8 mg/kg/day</td>
<td>DMH</td>
<td>Inhibits comment attributes and elevates the level of anti-oxidant enzymes</td>
<td>(Sengottuvelan et al., 2009)</td>
</tr>
</tbody>
</table>

Abbreviations: BaP; benzo alpha pyrene; DMH, 1,2-dimethylhydrazine; DSS, dextran sulphate sodium; H₂O₂, hydrogen peroxide; IL-6, interleukin-6; LPS, lipopolysaccharide; P.gingivalis LPS, Porphyromonas gingivalis lipopolysaccharide; KBrO₃, potassium bromate; ox-LDL, oxidized low-density lipoprotein; PMA, phorbol 12-myristate 13-acetate; STZ, streptozotocin; TNF, tumor necrosis factor; XO-xanthine oxidase.
### Table 3
Anti-inflammatory, cytoprotective, and DNA protective effects of flavonoids

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Dose/Concentration</th>
<th>Stimulation</th>
<th>Signaling pathways</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>LPS, PMA</td>
<td>Decreases the secretion of inflammatory cytokines in mouse macrophages</td>
<td>(Kowalski et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>10 or 25 µM</td>
<td>LPS</td>
<td>Attenuates the release of NF-kappa B and cytokines from human monocytes</td>
<td>(Nicholas et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>1-25 µM</td>
<td>LPS</td>
<td>Suppresses the expression of iNOS, COX-2, NF-kappa B, IKB and inflammatory cytokines in mouse macrophages</td>
<td>(Chen et al., 2007; Liang et al., 1999)</td>
</tr>
<tr>
<td></td>
<td>1-50 µM</td>
<td>Cytokines</td>
<td>Abrogates the activation of iNOS, COX-2, NF-kappa B, AP-1, and cell adhesion molecules in HUVECs</td>
<td>(Crespo et al., 2008; Gerritsen et al., 1995)</td>
</tr>
<tr>
<td></td>
<td>30 µM</td>
<td>PMA, PMACI</td>
<td>Down-regulates the release of inflammatory cytokines from mast cells</td>
<td>(Park et al., 2008)</td>
</tr>
<tr>
<td><strong>Cytoprotective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5-40 µM</td>
<td>IL-1β, IFN-γ</td>
<td>Attenuates cell death, production of NO, iNOS, NF-kappa B, ERK-1/2, STAT protein in RINmF5 and rat islets</td>
<td>(Kim et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>3.125-25 µM</td>
<td>Breast cancer</td>
<td>Induces apoptosis and arrest cell population at G1 phase in BT-474 cells</td>
<td>(Mai et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>50 µM</td>
<td>H$_2$O$_2$, Cu$^{2+}$-ox-LDL</td>
<td>Inhibits the expression of Bax-2 and caspase-3 but enhances Bcl-2 expression in HUVESc</td>
<td>(Choi et al., 2003; Jeong et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>200 µM</td>
<td>Peritoneal dialysis fluid,</td>
<td>prevents LDH release from mesothelial cells</td>
<td>(Riesenhuber et al., 2007)</td>
</tr>
<tr>
<td></td>
<td>15 mg/kg/day</td>
<td>STZ</td>
<td>Decreases NO and MDA in rat pancreas and erythrocytes</td>
<td>(Coskun et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>50, 100, 200 µM</td>
<td>LPS</td>
<td>Induces HO-1 and bilirubin production in mouse macrophages, ERK, P$^{53}$</td>
<td>(Lin et al., 2003)</td>
</tr>
<tr>
<td></td>
<td>3, 10, 30 µM</td>
<td>LPS, IFN-γ</td>
<td>Inhibits the activation of NO, iNOS, NF-kappa B, AP-1, and STAT-1 in BV-2 microglia</td>
<td>(Chen et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>40 and 60 µM</td>
<td>H$_2$O$_2$, low serum</td>
<td>Elevates HO-1 protein induction and abolishes ROS release in PC12 cells</td>
<td>(Hong et al., 2009)</td>
</tr>
<tr>
<td><strong>DNA protective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3-48 µM</td>
<td>Gamma radiation</td>
<td>Attenuates DNA strand breaks, MN frequency, and levels of TBARS in PBMSc</td>
<td>(Devipriya et al., 2008)</td>
</tr>
<tr>
<td></td>
<td>1, 10, 15, 100 µM</td>
<td>H$_2$O$_2$, BzP</td>
<td>Ameliorate DNA damage and formation of BPDE-DNA adduct in human lymphocytes</td>
<td>(Wilms et al., 2005)</td>
</tr>
<tr>
<td></td>
<td>2 % diet</td>
<td>AD</td>
<td>Reduces MN frequency and enhances buccal cell telomere length</td>
<td>(Thomas et al., 2009)</td>
</tr>
</tbody>
</table>

Abbreviations: AD, alzheimer’s disease; BzP, benzo alpha pyrene; Cu$^{2+}$-ox-LDL, copper oxidized low-density lipoprotein; H$_2$O$_2$, hydrogen peroxide; IFN-γ, interferon-gamma; IL-1β, interleukin-1 beta; LPS, lipopolysaccharide; PMA, phorbol 12-myristate 13-acetate; PMACI, PMA and calcium ionophore; STZ, streptozotocin